Pfizer is paying $650 million in upfront cash and making a $350 million equity investment in Arvinas, with another $1.4 billion in backloaded milestone payments.

and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...

In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs ...

1Q 2025 Business Highlights and Recent Developments Vepdegestrant: Oral PROTAC ER degrader: As part of Arvinas global collaboration with Pfizer, the companies: Reported positive topline data for ...

Pfizer has revealed that its much-anticipated ... Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared ...

We and Pfizer are working to evaluate future combination plans with the potential to maximize patient benefit and shareholder value," said John Houston, Chief Executive Officer. Arvinas also noted ...

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce.

1Q 2025 Business Highlights and Recent Developments Vepdegestrant: Oral PROTAC ER degrader: As part of Arvinas global collaboration with Pfizer, the companies: Reported positive topline data for ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, ...

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.